新生儿重症监护室万古霉素贝叶斯剂量优化软件评估
该研究回顾性纳入64例接受万古霉素治疗的新生儿重症监护室(NICU)患者,比较新生儿剂量模型(NDM)与儿科剂量模型(PDM)的贝叶斯预测性能。结果显示PDM预测准确性更高、谷浓度变异性更小,尤其在足月儿及矫正胎龄(PMA)<29周或>52周者中更准确;NDM在极早产儿和早期新生儿中持续高估谷浓度。
要点
- PDM较NDM预测万古霉素谷浓度更准确且变异性更小。
- PDM在足月儿及PMA<29周或>52周者中最准确。
- NDM在极早产儿和早期新生儿中高估谷浓度,导致AUC偏差更大。
核心结论
- PDM较NDM具有更优的预测性能,可能提高NICU患者万古霉素给药准确性,尤其PMA较大者。
研究设计与样本
- 回顾性研究,纳入64例接受万古霉素治疗的NICU患者,比较实测谷浓度与NDM及PDM的贝叶斯预测值。
主要发现
- PDM在不同胎龄(GA)和出生后年龄(PNA)组中预测准确性更高且谷浓度变异性更小。
- 分层分析显示PDM在足月儿及PMA<29周或>52周者中最准确。
- NDM在极早产儿和早期新生儿中持续高估谷浓度,导致更大AUC差异。
关键数值与推荐
- 模型性能采用中位绝对预测误差评估,并按GA、PNA和PMA分层。
临床怎么用
- NICU中可优先考虑使用PDM进行万古霉素贝叶斯剂量优化,尤其PMA较大的新生儿。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Infectious Diseases Society of America 2020 guidelines recommend Bayesian-guided area under the curve (AUC) monitoring for vancomycin dosing in pediatric patients. Our institution's neonatal intensive care unit (NICU) utilizes single-level kinetics to monitor AUC using 2 pharmacokinetic models validated in neonates and infants. Anecdotally, preterm infants corrected to a higher postmenstrual age (PMA) may be better suited to the pediatric dosing model (PDM) versus the neonatal dosing model (NDM). This study aims to identify which model is best suited to the NICU population based on factors including gestational age (GA), postnatal age (PNA), and PMA. METHODS: A retrospective review including 64 NICU patients who received vancomycin was conducted. Measured vancomycin trough concentrations were compared to Bayesian model predictions using both the NDM and PDM. Model performance was evaluated using median absolute prediction error and stratified by GA, PNA, and PMA. Predicted AUC and pharmacokinetic parameters were also compared between models. RESULTS: The PDM had greater predictive accuracy and less variability in trough concentrations across GA and PNA groups when compared to the NDM. Stratified analysis showed that the PDM was most accurate in term infants and those with a PMA of <29 or >52 weeks. The NDM consistently overpredicted trough levels in extremely preterm and early postnatal infants, leading to larger AUC discrepancies. Alternative models may improve predictive performance, particularly in high-risk neonatal subgroups. CONCLUSION: The PDM had superior predictive performance when compared to the NDM. Use of the PDM may improve vancomycin dosing accuracy in NICU patients, especially those with more advanced PMA.
引用
- Ivy C, Grube P, Lin L, et al. Evaluation of vancomycin Bayesian dose-optimizing software in a neonatal intensive care unit population. Am J Health Syst Pharm. 2026. PMID: 42784730. doi:10.1093/ajhp/zxag313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。